These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 3360048)
1. The effect of food on the absorption of slow-release isosorbide-5-mononitrate tablets. Thomson AH; Miller SH; Green ST; Whiting B Eur J Clin Pharmacol; 1988; 34(1):47-50. PubMed ID: 3360048 [TBL] [Abstract][Full Text] [Related]
2. [Bioavailability of sustained-release and nonsustained-release isosorbide-5-mononitrate]. Muck B; Bonn R; Rietbrock N Arzneimittelforschung; 1989 Oct; 39(10):1274-6. PubMed ID: 2610720 [TBL] [Abstract][Full Text] [Related]
3. [Bioavailability of isosorbide dinitrate and isosorbide-5-mononitrate under steady-state conditions]. Rietbrock N; Knoll J; Merz PG; Menke G Dtsch Med Wochenschr; 1985 Nov; 110(47):1821-5. PubMed ID: 3905327 [TBL] [Abstract][Full Text] [Related]
4. [Comparative pharmacokinetics and bioavailability of isosorbide dinitrate and its metabolites isosorbide 5- and 2-mononitrate from delayed-release preparations]. Geigenberger A; Degen J; Maier-Lenz H Arzneimittelforschung; 1982; 32(9):1138-40. PubMed ID: 6890839 [TBL] [Abstract][Full Text] [Related]
5. [Comparative study of the bioavailability and pharmacokinetics of isosorbide dinitrate formulations in retard form and in standard preparations by determination of isosorbide-5-mononitrate]. Lutz VD; Gielsdorf W; Rasper J; Jaeger H; Loew D Arzneimittelforschung; 1985; 35(4):730-4. PubMed ID: 4015739 [TBL] [Abstract][Full Text] [Related]
6. [Multiple dose pharmacokinetic and bioavailability studies of oral sustained release and conventional formulations of isosorbide-5-mononitrate in healthy volunteers]. Zhang Q; Huang X; Ji P; Fu L; Yan B; Wei S Yao Xue Xue Bao; 1998 May; 33(5):373-8. PubMed ID: 12017006 [TBL] [Abstract][Full Text] [Related]
7. [Bioavailability of isosorbide-5-mononitrate from delayed-action formulations]. Taylor T; Major RM; Leaf FC; Cook SC; Chasseaud LF; Darragh A; Lambe RF Arzneimittelforschung; 1984; 34(11):1584-7. PubMed ID: 6543135 [TBL] [Abstract][Full Text] [Related]
8. Effect of food on the oral bioavailability of isosorbide-5-mononitrate administered as an extended-release tablet. Kosoglou T; Kazierad DJ; Schentag JJ; Patrick JE; Heimark L; Radwanski E; Christopher D; Flannery BE; Affrime MB J Clin Pharmacol; 1995 Feb; 35(2):151-8. PubMed ID: 7751425 [TBL] [Abstract][Full Text] [Related]
9. [Pharmacokinetics and bioavailability of a new slow-release isosorbide-5-mononitrate system]. Gandini R; Cunietti E; Assereto R; Castoldi D; Tofanetti O; Baggio E Cardiologia; 1987 Nov; 32(11):1287-91. PubMed ID: 3447701 [No Abstract] [Full Text] [Related]
10. Sustained-release isosorbide mononitrate (50 mg): optimization of a once-daily dosage form for long-term treatment of angina pectoris. Bonn R Am J Cardiol; 1988 Mar; 61(9):12E-14E. PubMed ID: 3348135 [TBL] [Abstract][Full Text] [Related]
11. Bioavailability of isosorbide dinitrate and its two mononitrate metabolites from sustained-release formulations. Chasseaud LF; Doyle E; Taylor T; Darragh A; Lambe RF Int J Clin Pharmacol Ther Toxicol; 1983 Oct; 21(10):514-8. PubMed ID: 6642789 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of isosorbide-5-mononitrate after oral administration of an extended-release mononitrate formulation versus a standard dinitrate formulation. Kosoglou T; Patrick JE; Cohen A; Radwanski E; Christopher D; Affrime MB Clin Ther; 1995; 17(2):241-51. PubMed ID: 7614524 [TBL] [Abstract][Full Text] [Related]
13. Sex-related differences in the pharmacokinetics of isosorbide-5-mononitrate (60 mg) after repeated oral administration of two different original prolonged release formulations. Vree TB; Dammers E; Valducci R Int J Clin Pharmacol Ther; 2004 Aug; 42(8):463-72. PubMed ID: 15366327 [TBL] [Abstract][Full Text] [Related]
14. Isosorbide 5-mononitrate and isosorbide 2-mononitrate kinetics after intravenous and oral dosing. Straehl P; Galeazzi RL; Soliva M Clin Pharmacol Ther; 1984 Oct; 36(4):485-92. PubMed ID: 6478734 [TBL] [Abstract][Full Text] [Related]
15. Performance of a slow-release formulation of isosorbide-5-mononitrate (ISMO retard). Neugebauer G; Akpan W; Stemmle B; Jaeger H; Mosberg H; Lutz D Int J Clin Pharmacol Ther Toxicol; 1989 Jan; 27(1):34-8. PubMed ID: 2744904 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of oral isosorbide-5-mononitrate in patients with ischemic heart failure. Meissner A; Petersenn S; Heidemann HT; Osterkamp U; Simon R; Schulte HM Klin Wochenschr; 1991 Mar; 69(5):213-9. PubMed ID: 2033915 [TBL] [Abstract][Full Text] [Related]
17. [Pharmacokinetic profile and bioavailability of a new pharmaceutical formulation of isosorbide-5-mononitrate sustained-release formulation]. Skutta T; Böttcher B; Brandt L Arzneimittelforschung; 1989 Apr; 39(4):507-11. PubMed ID: 2751738 [TBL] [Abstract][Full Text] [Related]
18. A pharmacokinetic model for isosorbidedinitrate, isosorbide-2-mononitrate, and isosorbide-5-mononitrate. Smith D; Aldrich W; Dey M; Enever R; Warner R; Weierstall R Drug Metab Dispos; 1990; 18(4):429-34. PubMed ID: 1976063 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of novel immediate-/controlled-release tablets of isosorbide-5-mononitrate (5-ISMN): in vitro-in vivo correlation. Li X; Jiang Q; Du L; Li Y; Li M Pharmazie; 2014 Feb; 69(2):109-16. PubMed ID: 24640599 [TBL] [Abstract][Full Text] [Related]
20. Serum profile of isosorbide mononitrate after vaginal administration in the third trimester. Bates CD; Nicoll AE; Mullen AB; Mackenzie F; Thomson AJ; Norman JE BJOG; 2003 Jan; 110(1):64-7. PubMed ID: 12504938 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]